Does Robaxin (methocarbamol) increase the risk of seizures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Robaxin (Methocarbamol) Increase Seizure Risk?

Yes, methocarbamol can increase seizure risk, particularly in patients with pre-existing seizure disorders, and seizures have been documented as an adverse reaction to this medication.

FDA-Documented Seizure Risk

The FDA drug label explicitly lists seizures (including grand mal seizures) as an adverse reaction to methocarbamol 1. Critically, the onset of convulsive seizures during intravenous administration has been reported specifically in patients with seizure disorders 1. The FDA label states that although some clinicians have reported success using injectable Robaxin to terminate epileptiform seizures, its administration to patients with epilepsy is not recommended 1.

Seizures in Overdose Settings

Seizures are also documented as a manifestation of methocarbamol overdose, occurring alongside other CNS effects including nausea, drowsiness, blurred vision, hypotension, and coma 1. This reinforces that methocarbamol has inherent proconvulsant properties at higher doses or in susceptible individuals.

Clinical Context and Mechanism

Methocarbamol is a centrally-acting muscle relaxant with general CNS depressant effects 1. The mechanism by which it may precipitate seizures is not fully elucidated in the provided evidence, but the FDA notes that psychic trauma during procedures may be a contributing factor when seizures occur during administration 1.

Key Clinical Caveats

  • Avoid in patients with known seizure disorders: This is the most critical takeaway from the FDA labeling 1
  • CNS depression effects: The drug's CNS depressant properties may complicate seizure management and interact with other medications 1
  • Dose-related risk: Higher doses appear to carry greater risk, as evidenced by seizures occurring in overdose scenarios 1
  • Route considerations: The FDA specifically mentions seizure onset during IV administration, suggesting this route may carry particular risk 1

Risk-Benefit in Specific Populations

While methocarbamol has demonstrated efficacy in reducing hospital length of stay in trauma patients with rib fractures 2 and treating acute low back pain 3, these benefits must be weighed against seizure risk in susceptible individuals. In older adults, methocarbamol use is associated with increased injury risk (OR 1.42,95% CI 1.16-1.75) 4, which may compound concerns in patients with seizure disorders who are already at elevated fall risk.

Bottom line: Do not prescribe methocarbamol to patients with epilepsy or known seizure disorders. Exercise caution with higher doses in all patients, and be aware that seizures are a documented adverse effect of this medication.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.